Tufts receives patent for antibody treatment against hemolytic uremic syndrome

Feb 28, 2011

Researchers at the Cummings School of Veterinary Medicine have received U.S. patent approval for an antibody-based treatment for Hemolytic Uremic Syndrome (HUS), a potentially fatal outcome of E. coli poisoning and the leading cause of kidney failure in children.

HUS is caused by the forms of E. coli that produce Shiga toxins and are responsible for about 100,000 annual cases of illness in the United States alone. Typically, individuals will develop bloody diarrhea and recover—however, 5-15 percent of children, the elderly and individuals whose immune systems are compromised may develop HUS in addition after several days.

The condition causes kidney damage and can lead to chronic, irreversible kidney dysfunction, which can be fatal. HUS can also cause damage to the central nervous system. There is currently no cure for the condition.

The condition is believed to be caused by one of the two types of Shiga excreted by E. coli, known as Stx2 and Stx1. The Tufts approach to treating HUS, led by Dr. Saul Tzipori, director of the Cummings School's Division of Infectious Diseases, utilizes human monoclonal antibodies that seek out and bind to the Stx and, ultimately, neutralize it. In a 2004 study, Dr. Tzipori was able to show its efficacy both in vitro and in vivo using mice and pig models.

Other attempts to neutralize Stx have been attempted using other types of antibodies—chimeric and humanized—where mouse antibodies are fused with parts of human antibodies. However, Tzipori and his colleagues utilized antibodies from transgenic mice specially bred to express human antibodies—creating a safer, longer-lasting, and more effective treatment, Tzipori says.

"In addition to the other benefits, utilizing this approach of generating human enabled us to create a large number of them from which to select," said Distinguished Professor of Microbiology and Infectious Diseases Dr. Saul Tzipori.

The patent is currently licensed to Sarasota, Fla.-based Lakewood-Amedex Inc.

Explore further: New treatments for cancer, diabetes, and heart disease—you may have a pig to thank

Provided by Tufts University, Health Sciences

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Mice with human body's defenses

Oct 05, 2010

Therapeutic antibodies can be an efficient alternative when common drugs do not work anymore. However, antibodies obtained from blood of animals such as mice could not be used: The human immune system recognizes them as ...

Eliminating the source of asthma-causing immune molecules

May 10, 2010

Asthma and other allergic diseases are caused by inappropriate immune responses. Soluble IgE molecules, produced by immune cells known as B cells, are key immune mediators of these diseases. Therapeutic targeting of IgE in ...

Recommended for you

Educating on sickle cell risk

1 hour ago

Members of the public in sub-Saharan Africa who are carriers of the hereditary disease sickle cell disease must be educated aggressively through public health campaigns to raise awareness of the risks of parenting offspring ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.